Departments of *Imaging
§Medical Oncology, Dana Farber Cancer Institute
Departments of †Radiology
∥Medicine, Brigham and Women’s Hospital
‡Department of Biostatistics, Harvard Chan School of Public Health, Boston, MA
The investigators, M.N., B.E.J., and H.H., are supported by R01CA203636 (NCI), and M.N., J.L., and H.H. are supported by U01CA209414 (NCI).
M.N.: Consultant to Daiichi Sankyo, AstraZeneca; Research grant from Merck, Canon Medical Systems, AstraZeneca, Daiichi Sankyo; Honorarium from Roche. N.I.V.: Consultant to Sanofi. P.A.J.: Consultant for AstraZeneca, Boehringer Ingelheim, Pfizer, Roche/Genentech, ACEA Biosciences, Ignyta, LOXO Oncology, Eli Lilly, Araxes Biosciences, SFJ Pharmaceuticals, Voroni, Daiichi Sankyo, Biocartis, Novartis, Sanofi Oncology, Takeda Oncology, Silicon Therapeutics, and Mirati Therapeutics; Research Funding: AstraZeneca, Boehringer Ingelheim, PUMA, Eli Lilly, Takeda Oncology, Daiichi Sankyo, Astellas, and Revolution Medicines. Stock and other Ownership Interests: (including patents) in Gatekeeper Pharmaceuticals, LOXO Oncology, and Lab Corp. Patents, Royalties, Other Intellectual Property: Co-inventor on a Dana-Farber Cancer Institute–owned patent on EGFR mutations licensed to Lab Corp; postmarketing royalties received from this invention. H.H.: Research funding from Canon Inc., Canon Medical Systems Inc., and Konica-Minolta Inc.; Consultant to Canon Medical Systems Inc., and Mitsubishi Chemical Co. B.E.J.: Research support: Canon Medical Systems, Novartis, Sola Fund for Lung Cancer Research, Shuster Lung Cancer Research; postmarketing royalties for EGFR Mutation testing; Dana-Farber Cancer Institute. The remaining authors declare no conflicts of interest.
Correspondence to: Mizuki Nishino, MD, MPH, Department of Imaging, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215 (e-mail: [email protected]).
